Abstract:Objective: To assess the efficacy and tolerability of quetiapine in Chinese patients hospitalized with acute bipolar mania.Methods: This was a 4-week, multicenter, randomized, double-blind, lithium-controlled, parallel-group study. Secondary endpoints in the primary analysis were: response rate (>= 50% decrease from baseline in YMRS total score) and remission rate as defined using 3 criteria: YMRS total score <= 12, YMRS total score <= 12 + MADRS total score <= 8, and YMRS total score <= 8. Other measures included: change from baseline at Day 28 in YMRS, PANSS, and MADRS total score. Adverse event (AE) data were collected throughout the study.Results: 73 (94.8%) quetiapine and 62 (80.5%) lithium patients completed the study. Mean (SD) quetiapine doses for the ITT population and responders were 648.2 (111.84) mg/day and 637.5 (118.78) mg/day, respectively, while mean lithium concentrations for the ITT population and responders were 0.80 (0.28) mmol/L and 0.80 (0.22) mmol/L, respectively. Of patients who responded to quetiapine at Day 28, 88.3% were receiving 600-800 mg/day. At Day 28 YMRS response rate was significantly greater with quetiapine than lithium (77.9% vs. 59.7%, p = 0.0132), and remission rates using the 3 criteria were significantly greater with quetiapine than lithium: YMRS total score <= 12 (70.1% vs. 48.1%, p = 0.0071), YMRS <= 12 + MADRS <= 8 (70.1% vs. 48.1%; p = 0.0071), and YMRS <= 8 (51.9% vs. 32.5%; p = 0.0147). Significant decreases were observed in PANSS, YMRS, and MADRS total scores for both groups. The most common AEs experienced by patients receiving quetiapine were constipation, dizziness, diarrhea, alanine aminotransferase increase, palpitations, aspartate aminotransferase increase, pharyngolaryngeal pain, upper respiratory tract infection and dry mouth. In patients receiving lithium, the most common AEs were nausea (16.9%), constipation (13.0%), vomiting (13.0%), nasopharyngitis (11.7%), dizziness (6.5%), diarrhea (6.5%), and upper respiratory tract infection (6.5%).Conclusion: Quetiapine was shown to be clinically effective in patients with acute bipolar mania. There were side effects with quetiapine similar to those reported in other studies that included other ethnic populations of patients.

Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study

Efficacy and Safety of Quetiapine Extended Release Monotherapy in Bipolar Depression: a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

The efficacy and safety of venlafaxine XR in treating patients with major depression in a multicenter,open-label, 16 week study

Efficacy of Quetiapine Monotherapy and Combination Therapy for Patients with Bipolar Depression with Mixed Features: A Randomized Controlled Pilot Study

Efficacy and Tolerability of Once-Daily Extended Release Quetiapine Fumarate in Acute Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study.

Efficacy and Safety of Quetiapine-Xr As Monotherapy or Adjunctive Therapy to a Mood Stabilizer in Acute Bipolar Depression with Generalized Anxiety Disorder and Other Comorbidities: a Randomized, Placebo-Controlled Trial.

A Randomized, Placebo-Controlled Pilot Study of Quetiapine-XR Monotherapy or Adjunctive Therapy to Antidepressant in Acute Major Depressive Disorder with Current Generalized Anxiety Disorder.

Lurasidone Versus Quetiapine for Cognitive Impairments in Young Patients with Bipolar Depression: A Randomized, Controlled Study

Comparisons of the Tolerability and Sensitivity of Quetiapine-Xr in the Acute Treatment of Schizophrenia, Bipolar Mania, Bipolar Depression, Major Depressive Disorder, and Generalized Anxiety Disorder

EFFICACY AND TOLERABILITY OF QUETIAPINE XR 400/600/800MG/DAY IN ACUTE SCHIZOPHRENIA: A POST-HOC ANALYSIS OF DATA FROM TWO POOLED RANDOMISED STUDIES

P03-242 - Efficacy and tolerability of quetiapine XR 400/600/800mg/day in acute schizophrenia: a post-hoc analysis of data from two pooled randomised studies

Efficacy of Repetitive Transcranial Magnetic Stimulation with Quetiapine in Treating Bipolar II Depression: a Randomized, Double-Blinded, Control Study

Efficacy of Once-Daily Extended Release Quetiapine Fumarate Across Symptom Domains in Schizophrenia

Efficacy and Safety of Quetiapine in the Treatment of Bipolar Acute Mania: a Randomized, Double-Blind, Lithium-Controlled Multicenter Study

A 6-Week, Multicenter, Double-Blind, Double-Dummy, Chlorpromazine-Controlled Non-Inferiorityrandomized Phase Iiitrial to Evaluate the Efficacy and Safety of Quetiapine Fumarate (SEROQUEL) Extended-Release (XR) in the Treatment of Patients with Schizophrenia and Acute Episodes.

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial

Post-marketing surveillance of quetiapine fumarate extended-release tablets in patients with bipolar depression

An Open Label, 4-Week, Randomised, Multi-Centre, Phase IV Study to Compare the Efficacy and Safety of Quetiapine Fumarate (seroqueltm) As Mono-Therapy or Adjunct to Lithium in the Treatment of Patients with Acute Mania in Bipolar Disorder

Response and Remission Rates in Chinese Patients with Bipolar Mania Treated for 4 Weeks with Either Quetiapine or Lithium: a Randomized and Double-Blind Study.

Use of Mental Health Telemetry to Enhance Identification and Predictive Value of Early Changes During Augmentation Treatment of Major Depression

Efficacy and safety of quetiapine augmentation of antidepressants on depression